Home > Faculty > Chemical Biology > 正文 >
Zhengying Pan

  • Zhengying Pan

  • Principal Investigator, Associate Professor
  • Tel:+86-755-2603-5566
  • Email:panzy@pkusz.edu.cn
  • Web:http://web.pkusz.edu.cn/pan
  • Education & Experience

    2009 – present        Distinguished Research Fellow, Shenzhen Graduate School, Peking University, Shenzhen
    2008 – 2009            Research Scientist II, OPTI Medical Systems, a subsidiary of IDEXX Laboratories, Roswell
    2006 – 2007             Senior Scientist, AtheroGenics, Alpharetta
    2002 – 2006             Senior/Staff Scientist, Celera Genomics, South San Francisco
    2000 – 2002             Postdoctoral Researcher, Stanford University, Stanford
    1994 – 1999             Ph.D., Columbia University, New York
    1989 – 1994             B.S., Peking University, Beijing

  • Awards & Honors

    2013        Life Science and Chemistry Scholar Award, Wuxi PharmaTech, Shanghai
    2005        Celera DNA Award, Celera Genomics, South San Francisco, CA 
    1994        Outstanding Graduate Award  Peking University, Beijing

  • Research Fields

    Our group is trail-blazing a novel approach to study human chemical biology and advance drug discovery. We combine cutting-edge medicinal chemistry and emerging chemical proteomics to advance our understanding of diseases and discover new therapeutic agents. Initial successes include a first-in-class “breakthrough” drug approved in the US and EU, and small molecule probes for living cell imaging and applications in human samples.

    1.  Medicinal Chemistry on Oncology Targets
    For many types of human cancer, abnormal kinase activities are rampant and well documented by large quantity of biological data. We focus our medicinal chemistry efforts on this class of key drug targets. We’re developing compounds targeting kinase catalytic domain with various binding modes and implementing new assays aiming at other domains of kinases.
     2.  Chemical Proteomics for Kinome – Precision Tools for Studying Signal Transduction
    Cellular activities are greatly influenced by biological and chemical signals. Kinases are major mediators of signal transduction pathways. Our main goal is to enable direct detection of kinase activities at their endogenous levels in native living human cells. We’re developing novel activity/affinity probes for kinases and a method to capture physiological substrates of these marvelous enzymes to understand temporal and spatial controls in cellular circuitry.
     3.  Synthetic Methodology Development
    One of this group’s scientific foundations is organic synthesis. Despite amazing progress in this field, there still are great needs to discover new methods to provide easy access to clinically relevant bioactive molecules. 
  • Selected Publications

    1.  Ding, N.; Li, X.; Shi, Y.; Ping, L.; Wu, L.; Fu, K.; Feng, L.; Zheng, X.; Song, Y.*; Pan, Z. *; Zhu, J.* “Irreversible dual inhibitory mode: the novel Btk inhibitor PLS-123 demonstrates promising anti-tumor activity in human B-cell lymphoma.” Oncotarget 2015, published online Apr 14.
    2.  Zhang Q, Liu H, Pan Z.* “A general approach for the development of fluorogenic probes suitable for no-wash imaging of kinases in live cells” Chem. Commun. 2014, 50, 15319.
    3.  Liu H, Yang Z, Pan Z.* “Synthesis of Highly Substituted Imidazolidine-2,4-dione (Hydantoin) through Tf2O-Mediated Dual Activation of Boc-Protected Dipeptidyl Compounds” Org. Lett. 2014, 16, 5902.
    4.  Zhou Y, Guo T, Tang G, Wu H, Wong N-K, Pan Z.* “Site-selective Protein Immobilization by Covalent Modification of GST Fusion Proteins” Bioconjugate Chem. 2014, 25, 1911.
    5.  Li X, Zuo Y, Tang G, Wang Y, Zhou Y, Wang X, Guo T, Xia M, Ding N, Pan Z.* “Discovery of a Series of 2,5-Diaminopyrimidine Covalent Irreversible Inhibitors of Bruton’s Tyrosine Kinase with in Vivo Antitumor Activity” J. Med. Chem. 2014, 57, 5112.
    6.  Zhou Y, Guo T, Li X, Dong Y, Galatsis P, Johnson D S, Pan Z.* “Discovery of selective 2,4-diaminopyrimidinebased photoaffinity probes for glyoxalase I” Med. Chem. Commun. 2014, 5, 352. (Invited for the thematic issue on “Chemical biology for target identification and validation”)
    7.  Zheng J, Lin S, Zhu X, Jiang B*, Yang Z*, Pan Z.* “Reductant-directed formation of PS-PAMAM-supported gold nanoparticles for use as highly active and recyclable catalysts for the aerobic oxidation of alcohols and the homocoupling of phenylboronic acids.” Chem. Commun. 2012, 48, 6235.
    8.  Honigberg, L.A.; Smith, A.M.; Sirisawad, M.; Verner, E.; Loury, D.; Chang, B.; Li, S.; Pan, Z.; Thamm, D.H.; Miller, R.A.; Buggy, J.J. “The Bruton Tyrosine Kinase Inhibitor PCI-32765 Blocks B-cell Activation and Is Efficacious in Models of Autoimmune Disease and B-cell Malignancy” Proc. Natl. Acad. Sci. USA 2010, 107, 13075.
    9.  Pan, Z.; Scheerens, H.; Li, S.-J.; Schultz, B. E.; Sprengeler, P. A.; Burrill, L. C.; Mendonca, R. V.; Sweeney, M. D.; Scott, K. C. K.; Grothaus, P. G.; Jeffery, D. A.; Spoerke, J. M.; Honigberg, L. A.; Peter R. Young, Dalrymple, S. A. and Palmer, J. T. “Discovery of Selective Irreversible Inhibitors for Bruton’s Tyrosine Kinase” ChemMedChem 2007, 15: 58. (corresponding author)
    10.  Pan, Z.; Jeffery, D. A.; Chehade, K.; Beltman, J.; Clark, J. M.; Grothaus, P. G.; Bogyo, M. and Baruch, A. “Development of Activity-based Probes for Trypsin-family Serine Proteases” Bioorg. Med. Chem. Lett. 2006, 16: 2882. (co-corresponding author)
     
    PATENTS
    Over 20 international patents and patent applications